BioMedNewsBreaks – Astrotech Corp. (NASDAQ: ASTC), Subsidiary Set to Spotlight Tracer 1000 Trace Detector at Leading Security Trade Event

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its wholly owned subsidiary, 1st Detect Corporation, will be showcasing the TRACER 1000 Narcotics Trace Detector (“NTD”) and Explosives Trace Detector (“ETD”) at the International Security Conference and Exposition. Known as ISC West, the conference and expo is slated to run April 9–12, 2024, in Las Vegas; the event is the one of the leading comprehensive security trade events in the nation and will be attended by key security and public-safety professionals. A high-performance laboratory instrument powered by Astrotech Mass Spectrometer Technology(TM), the TRACER 1000 can detect trace levels of narcotics or explosive compounds in seconds. The device is the first mass spectrometry-based ETD to receive European Civil Aviation Conference (“ECAC”) certification for both checkpoint and cargo security and can be used in an array of sectors, including airports, border security, checkpoint, cargo, infrastructure security, correctional facilities, military and law enforcement. “We are extremely excited to share our user-friendly mass spectrometer, the TRACER 1000, which is powered by our AMS Technology, with leading industry experts and security-industry professionals at the ISC West conference,” said Astrotech chair, CEO and CTO Thomas B. Pickens III in the press release. “This allows us a platform to reach those in the industry across various markets, such as security, checkpoint, military and law enforcement, that strive for quality instrumentation, that require a minimum amount of maintenance and [that] want accurate but rapid detection.”

To view the full press release, visit https://ibn.fm/wF3cu

About Astrotech Corp.

Astrotech is an innovative science and technology company that invents, acquires and commercializes technological innovations while building scalable companies to maximize shareholder value. 1st Detect develops, manufactures and sells trace detectors for use in the security and detection market. For more information, please visit www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 

Soligenix (NASDAQ: SNGX) announced the publication of positive results from its comparability study evaluating HyBryte(TM) versus Valchlor(R) for the treatment…

1 hour ago

BioMedNewsBreaks — NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) Wins BOLD Awards VII Healthcare Honor, Engages IBN For Investor Outreach 

This article has been disseminated on behalf of NurExone Biologic and may include paid advertising.  NurExone Biologic (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) announced…

1 hour ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Partners with TechForce Robotics to Advance AI-Enabled GMP Automation Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced a strategic partnership with TechForce Robotics to advance commercialization of…

2 hours ago

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year 

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the…

1 day ago

BioMedNewsBreaks — HeartBeam Inc.’s (NASDAQ: BEAT) ‘Significant Turning Point’ Spotlighted in Recent Article

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed Joseph Gunnar & Co.’s…

2 days ago

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results

Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing…

2 days ago